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http://dx.doi.org/10.1016/j.jpurol.20
1477-5131/ª 2014 Journal of PediatriAbstract Objective: Our aim was to evaluate the efficacy and safety of single endoscopic in-
jection of Vantris in young girls affected by primary vesicoureteral reflux (VUR) at more than 2
years of prospective follow-up.
Material and methods: Over the last 4 years, 73 girls with primary VUR of grades (G) IeIV un-
derwent a single endoscopic injection of Vantris. The mean age was 8.48 (SDZ 4.8) years. VUR
was unilateral in 73 and bilateral in 13 patients, comprising 86 renal refluxing units (RRUs). Pre-
operative evaluation consisted of: blood biochemistry, urine analysis and culture, ultrasound
scan, voiding cystourethrogram (VCUG), and dimercaptosuccinic acid (DMSA) renal isotope
scan. Patients were followed using ultrasound scans at 1 month and every 3 months for the first
year and then 2 years after injection. Direct radionuclide cystography with technetium per-
technetate was performed at 3 and 12 months after injection. VCUG was performed only in
confirmed cases of failure and downgraded VUR at 3, 12, and 24 months after endoscopic
correction.
Results: Sixty-nine (95%), 61 (83.4%), and 52 (71%) patients completed 3, 12, and 24 months’
follow-up respectively. VUR was corrected and downgraded to G I in 81% and 3.3% of RRUs at
3 months’ follow-up. The corrected and downgraded RRUs at 12 and 24 months’ follow-up
were 77%, 10%, and 77%, 11% respectively. De novo contralateral G I VUR was demonstrated
in 8.6% of normal ureters. Contralateral GI VUR with normal DMSA isotope renal scans
was resolved in 71% of RRUs. Febrile urinary tract infection decreased to 4.1% in the pa-
tients.phrology Research Center, No#103, 9th Boostan St., Pasdaran Ave, Tehran, Islamic Republic of Iran.
oo.com (F. Sharifiaghdas).
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Endoscopic correction of primary VUR by using Vantris 1033Conclusion: According to our study, a single Vantris injection provides a high level of effi-
cacy and safety in the treatment of primary G IeIV VUR in young girls, at 2 years’ prospec-
tive follow-up.
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Vesicoureteral reflux (VUR) is the most common urologic
anomaly in children and affects 1% of normal children [1].
Urinary tract infection (UTI) accompanied by VUR pre-
disposes the child to acute pyelonephritis and possible
subsequent renal scars [2].
Subureteric transurethral injection was introduced by
Matouscheck [3] as a minimally invasive procedure in the
treatment of VUR.
Since then, different materials have been proposed and
injected. Dextranomer/hyaluronic acid (Dx/HA) copolymer
(Deflux, Q-Med Scandinavia, Uppsala, Sweden) was
approved by the Food and Drug Administration, and grad-
ually endoscopic management of VUR became the first-line
treatment in many medical centers [4e6]. According to the
published reports, the overall success rate is between 60%
and 93% [5]. The results are dependent to VUR grade, the
surgeon’s level of experience, and repeated injections
[6e8].
Complications after injection are infrequent, and
include de novo contralateral VUR and de novo hydro-
ureteronephrosis at the affected side [8]. The estimated
recurrence rate after successful Dx/HA treatment has been
reported to be between 13% and 21%; the long-term dura-
bility of bulking agents is an evolving subject [9].
Polyacrylate polyalcohol copolymer (PPC, Vantris,
Promedon, Cordoba, Argentina) is a relatively new non-
biodegradable substance. There are a few clinical studies
that report promising short and medium-term results with
Vantris injection [10e12].
Herein, we report our experience with a single endo-
scopic injection of Vantris in young girls affected by pri-
mary VUR, and evaluate the success rate and complication
rate at more than 2 years’ prospective follow-up.
Materials and methods
From February 2010 to October 2013 through a prospective
clinical study we treated 73 girls affected by primary VUR
of grades (G) IeIV. The study was approved by the Ethics
Committee of the UrologyeNephrology Research Center.
VUR was diagnosed as a result of UTI in 85% and during the
evaluation of prenatal hydronephrosis in 15% of patients.
The grade of VUR was based on the voiding cystour-
ethrogram (VCUG) images, according to the international
classification system (International Reflux Study
Committee).
Dimercaptosuccinic acid (DMSA) isotope renal scan was
performed to detect renal scars at least 6 months after the
last febrile UTI. Total kidney uptake of 45%e55% was
considered normal. Renal uptake of 20%e45% wasconsidered moderate, and renal uptake of below 20% was
considered poor function of the kidney.
The pre-operative evaluation consisted of history and
physical examination, blood biochemistry, urine analysis
and culture, ultrasound scan, VCUG, and DMSA isotope
renal scan.
Inclusion criteria were break-through infections while
on antibiotic prophylaxis, new renal parenchymal scars
and/or deterioration of renal function, and incompliance
of the patient or parents while on medical treatment.
Exclusion criteria were past medical history of sub-trigonal
injection therapy or anti-reflux open surgery, evidence of
possible secondary VUR (chronic severe voiding dysfunc-
tion, daytime incontinence, and constipation), presence of
other urinary tract anomalies (ureterocele, complete
duplex system, ectopic ureter, bladder diverticulum), VUR
of grade V, active UTI at the time of intervention and male
gender. All families gave fully written informed consent.
Injection was performed in an outpatient setting under
general anesthesia. The 1-mL syringe containing the
Vantris gel was connected to a 3.7F needle. In patients
with G IeIII VUR, the usual technique of sub-ureteric
transurethral injection was used. The needle was passed
transurethrally into the bladder, and introduced sub-
mucosally under the ureteral orifice at the 6 o’clock po-
sition [5]. In case of a widely open ureteral orifice or G IV
VUR, the injection was performed submucosally inside the
ureteral orifice [7]. The patients were discharged on the
same day, and all received antibiotic prophylaxis until the
result of postoperative images that confirmed resolution of
VUR.
The patients were followed by upper and lower urinary
tract ultrasound scan on the first postoperative day to rule
out iatrogenic obstruction, which was repeated every 3
months for the first year, and then 2 years after the pro-
cedure. Urine culture was performed on the fourth post-
operative week and every 3 months for the first year and
then 2 years after the procedure. In case of any lower
urinary tract symptoms urine culture and ultrasound scan
were repeated. In order to reduce the radiation exposure, a
direct radionuclide cystogram (DRNC) was performed using
technetium-99m (99mTC) pertechnetate, at the third and
12th months after the operation. Antibiotic prophylaxis was
stopped if DRNC was a cure for VUR. If there was persis-
tence or downgrading of VUR, standard VCUG was per-
formed for grading of VUR. At more than 2 years’ follow-up,
an ultrasound scan and urine culture were requested in all
available patients. Because of ethical concerns, VCUG was
performed on known cases of treatment failure or down-
graded VUR at 1-year follow-up, abnormal findings on ul-
trasound scan which would suggest recurrence of VUR, and
positive urine cultures (after a treatment course of
antibiotics).
Table 2 Outcome of a single Vantris injection at 3 months
of follow-up.
Grade No (RRUs) Corrected Downgraded (G I)
I 3 3 (100%) e
II 9 9 (100%) e
III 51 41 (80%) 2 (3.9%)
IV 17 12 (70%) 1 (1.3%)
Table 3 Overall outcome of single Vantris injection at 1
year of follow-up.
Grade No (RRUs) Corrected Downgraded (G I)
I 2 2 (100%) e
II 7 7 (100%) e
III 43 33 (76%) 5 (11%)
IV 16 11 (68%) 2 (12%)
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Seventy-three patients were prospectively enrolled on the
clinical trial. VUR was unilateral in 73 and bilateral in 13,
comprising 86 RRUs. There were 14 contralateral RRUs with
G I VUR and normal DMSA renal scans. Mean age was 8.48
(SDZ 4.8) years old. VUR was G I in three (3.5%), G II in 10
(11.6%), G III in 54 (62.7%), and G IV in 19 (22%) (Table 1).
Mean injected volume of Vantris per ureter was 0.6 mL
(0.4e1.0 mL). The procedure was uneventful in all pa-
tients. The mean operative time was 10 (8e19 range) min.
Mean follow up duration was 29.5 (SD Z 4.2) months.
Seven (9.5%) and five (6.8%) patients complained of
postoperative gross hematuria and mild dysuria respec-
tively, which gradually resolved 1 week after the proce-
dure. One patient complained of mild flank pain, resolved
at the first postoperative day. A urinary tract ultrasound
scan was within normal limits in all patients 24 h after the
procedure. Three (4.1%) patients developed febrile UTI
during the first 3 months after the operation. Afebrile UTI
was recorded in four (5.6%) patients at 1-year follow up.
Sixty-nine (94.5%) patients completed the 3-month
follow-up. VUR was corrected in 65 out of 80 (81%) RRUs,
and downgraded to G I in three (3.3%), who were taken off
antibiotic prophylaxis (Table 2).
Sixty-one (83.4%) patients completed the 1-year follow
up. VUR was corrected in 53 out of 68 (77%) RRUs, and
downgraded to G I in 7 (10%) RRUs. There were no new
failures at the 12-month follow-up (Table 3).
Ten out of 14 (71.4%) contralateral G I VUR with normal
DMSA renal scans resolved spontaneously and remained
stable at the 1-year follow-up. De novo G I VUR was docu-
mented in four (8.6%) contralateral normal ureters at both
the 3- and 12-month follow-up.
Fifty-two (71%) patients with 56 RRUs completed 2 years
of follow-up (Table 4). Six patients (7 RRUs) were among theTable 1 Demographic data and patient characteristics.
Variables No. of patients
Gender
Female 73
Mean age (y)  SD 8.4  4.8
No of laterality (RRUs)
Unilateral 73
Bilateral 13
Grade of VUR (RRUs) No
I 3 (3.5%)
II 10 (11.6%)
III 54 (62.7%)
IV 19 (22%)
Renal function (RRUs)
Normal 48 (55.8%)
Moderate 32 (37.1%)
Poor 6 (6.9%)
Mean injected volume (mL) 0.6 (range 0.4e1.0)
Indications for surgery
Breakthrough UTI 40 (54.6%)
New renal parenchymal scars 24 (32.8%)
Parental request 9 (12.3%)failures (12%), three with G III and four with G IV. Two pa-
tients (2 RRUs) had G III VUR at the 1-year follow-up and
downgraded G I at the 24-month follow-up. Three patients (3
RRUs) had G I VUR at the 12- and 24-month follow-up (overall
11% G I); 41 patients (44 RRUs) had normal ultrasound scans
and negative urine cultures, with normal bladder isotope
scans at both the 3- and the 12-month follow-up. These cases
were considered to have been treated, and the third bladder
isotope scan was not performed. According to these criteria
there were no new failures at the 24-month follow-up.
Discussion
The efficacy and durability of open surgical approaches
have been confirmed over many decades. However, ure-
teral reimplantation techniques are considered invasive,
with a low but important risk of complications [13]. Intro-
duction of bulking agents, the minimally invasive approach,
has brought new hope in the management of VUR.
The primary goal of VUR treatment is to prevent kidney
damage. Different injectable materials have been used,
including synthetic and biologic materials, polymers and
biopolymers.
A significant number of published clinical trials have
focused on the efficacy of dextranomer hyaluronic acid
(Dx/HA) copolymer, either used as a single agent or
compared with other commercially available bulking
agents.
Nortes Cano et al. [14] published their results after 9
years of experience with endoscopic correction of primaryTable 4 Overall outcome of rate of single Vantris injec-
tion at 2 years of follow-up.
No:
(patients)
No:
(RRUs)
Corrected Failure Downgraded
to GI
52 56 44 (77%) 7 (12%) 5 (11%)
G III Z 3
G IV Z 4
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Macroplastique, and Coaptite. A total of 989 patients (1498
RRUs) were followed. VUR G III was the most common. The
success rate was reported to be 91%, 88.2%, and 33.4% for
Deflux, Macroplastique, and Coaptite, respectively [14].
Coletta et al. [15] reported their short- and long-term re-
sults with endoscopic injection of Deflux. A total of 126
patients (198 RRUs) with primary VUR were treated and
followed. Complete resolution, downgrading, and failure
rate were reported in 68%, 10%, and 21% of RRUs, respec-
tively [15]. Kaye JD reported the results of endoscopic in-
jection of Deflux in 336 patients affected by primary VUR.
He performed the new injection technique of double
hydrodistention (HIT) [7]. The patients were followed for 12
months. The clinical success rate (no evidence of febrile
UTI) and radiologic success rate (no evidence of VUR on
VCUG) were reported to be 94% and 82%, respectively [16].
However, in recent years there have been published reports
of recurrence of VUR with Dx/HA at longer follow-up after
successful correction, which may be related to the biode-
gradable nature of the material.
Schemedding et al. [17] published the results of a
prospective multicenter trial. A total of 284 patients (424
RRUs) were treated endoscopically by injection of Deflux.
They were followed for 6e36 months. VUR was corrected
in 68% of RRUs, with a recurrence rate of 21% [17].
Sedberry-Ross et al. [18], reported a 27% recurrence rate
of VUR with Deflux. Lee et al. [9] followed their patients
for 1 year and reported a recurrence rate of 26% after
successful correction with Deflux. The above-mentioned
authors recommended long-term follow-up of patients
who had undergone a successful endoscopic injection of
Deflux, especially beyond the first 3 years after the
operation.
PPC is a rather new synthetic non-biodegradable
hydrogel with amorphous particles. The average diameter
of the particles is 320 mm (97% of the particles are more
than 110 mm in diameter). The surface electronegativity of
the particles stimulates the formation of a thin capsule
around the injected material. Both characteristics, the
particle size and capsule formation, reduce the chance of
local and distant migration [10].
Injection of this substance is performed easily through a
3.7F, 23-gauge needle, and there is no need for a pump
device.
When we conducted this prospective study, the cost of
bulking agents was not covered of by medical insurance
companies in our country, and parents/guardians paid for
treatment. The price of Dx/HA was more than two times
that of Vantris, so the cost of treatment was an important
concern. VUR of G V was excluded from the clinical trial for
two reasons: first, G V VUR is less common, with less
response to treatment by any approach (open surgery and
endoscopic injections); and, second, there was a proba-
bility of more than one injection session, perhaps two to
three times to correct the VUR, which would increase the
cost and burden on parents.
According to the decision made by the board of the
UrologyeNephrology Research Center, as most of our pa-
tients were young girls only female patients were included.
The indication for endoscopic correction of VUR was febrile
UTI while on antibiotic prophylaxis in 54.6% of the patients.After successful correction of VUR, only 4.3% of the pa-
tients demonstrated febrile UTI.
There are a few clinical studies with Vantris in the treat-
ment of VUR. Ormaechea et al. [10] treated 83 patients
during a multicenter trial. Sixty-one patients (18 males, 43
females) (88 RRUs) with an average age of 58 months
completed a 1-year follow-up. VUR grade was IIeV, and 83%
were G IIeIII VUR. The mean injected volume per ureter was
0.76 mL (0.2e1.6 mL). After an average follow-up period of
20 months (range 16e24 months) VUR was cured and down-
graded to G I in 88.6% and 6.8% RRUs respectively. The
postoperative complication rate was low and iatrogenic
ureteral obstruction was reported in one patient treated by
open extravesical ureteral reimplantation [10].
Chertin et al. reported their preliminary data with
endoscopic injection of Vantris. Thirty-eight patients (11
males, 27 females) with 59 RRUs were treated. The mean
age was 5.3  3.8 years. VUR was grades IeV. Seventeen
complex cases (3 duplex systems, 1 with prune belly syn-
drome and 13 after failed previous correction with Deflux)
were included. After 3 months’ of follow-up, reflux was
corrected in 94.9% of RRUs. Twenty-one out of 38 patients
completed 1-year follow-up. Eight out of 21 patients un-
derwent radionuclide cystography, and no recurrence of
VUR was recorded [11].
In 2013, Chertin et al. [12] reported 3 years of pro-
spective follow-up with endoscopic injection of Vantris. A
total of 109 children (37 males, 72 females) with 165 RRUs
underwent the procedure. The mean age was 6.2  3.4
years. VCUG was performed at 3, 12, and 36 months after
the operation; 84.2% and 15.8% of RRUs were primary and
complex cases, respectively. VCUG was performed in 32 out
of 71 children (39.1%) who completed 1-year follow up, and
in six of 15 (40%) who completed the 3-year follow-up. VUR
was corrected in 92.7% and 4.2% of RRUs after the first and
the second endoscopic injection of Vantris. Ureteral
obstruction was recorded in two patients, resolved by
insertion of stent in one case and open ureteral reimplan-
tation in the other one [12].
Our clinical results are close to the few above-
mentioned clinical trials with endoscopic injection of
Vantris, with a correction and an improvement rate of 77%
and 11% respectively. There are some differences and
limitations to our study. G V VUR, male gender, and com-
plex cases were excluded. Also, the injected volume of
Vantris per ureter was limited to a maximum of 1 mL. By
increasing the injected volume of Vantris per ureter and the
number of treatment sessions perhaps we would improve
our clinical results. Also, in contrast to other studies with
Vantris, there was no clinical and radiologic evidence of
ureteral obstruction in our case series.
Another important limitation in our study is the small
number of patients and RRUs. Perhaps a multicenter
comparative study with a large number of patients and a
longer period of follow-up which covers all subgroups of
VUR will answer these questions.Conclusion
In this preliminary study, Vantris injection provides a high
level of efficacy and safety in the treatment of G IeIV VUR
1036 F. Sharifiaghdas et al.at 2 years’ follow-up in a subgroup of young girls affected
by primary VUR. Multicenter trials with a larger number of
RRUs are needed to establish the results.
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